Brain specific proteins in cerebrospinal fluid (CSF): Factors influencing their concentration in CSF and clinical relevance;ZNS-proteine im liquor: Einflussfaktoren auf ihre konzentration im liquor und klinische relevanz

LaboratoriumsMedizin

Volumn 29, Issue 6, 2005, Pages 421-428

  Tumani, Hayrettin ^a   Brettschneider, Johannes ^a  

^a Rehabilitationskrankenhaus Ulm gGmbH   (Germany)

Author keywords

Blood brain barrier; Blood CSF barrier; Brain specific proteins; Cerebrospinal fluid

Indexed keywords

BRAIN PROTEIN; TAU PROTEIN;

BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID DRAINAGE; CEREBROSPINAL FLUID FLOW; CEREBROSPINAL FLUID PRESSURE; DEMENTIA; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE MARKER; HUMAN; LABORATORY TEST; MEDICAL INFORMATION; MOLECULAR WEIGHT; NEUROLOGIC DISEASE; REVIEW;

EID: 29344452502     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2005.057     Document Type: Review

References (45)

1. Mäder M, Soerensen K, Wiedmann T, Dickmann U, Felgenhauer K. Neuronal acetylcholinesterase levels in cerebrospinal fluid and serum determined by a specific and sensitive immunoassay. Eur J Clin Chem Clin Biochem 1991;29:51-5.
2. Massaro AR, Scivoletto G, Tonali P. Cerebrospinal fluid markers in neurological disorders. Ital J Neurol Sci 1990;11:537-47.
3. Vermuyten K, Lowenthal A, Karcher D. Detection of neuron specific enolase concentrations in cerebrospinal fluid from patients with neurological disorders by means of a sensitive enzyme immunoassay. Clin Chim Acta 1990;187:69-78.
4. Felgenhauer K, Beuche W. Labordiagnostik neurologischer Erkrankungen. Stuttgart (Deutschland): Thieme 1999.
5. Goldstein GW, Betz AL. The blood-brain barrier. Sci Am 1986;255:74-83.
6. Westergaard E. The blood-brain barrier to horseradish peroxidase under normal and experimental conditions. Acta Neuropathol Berl 1977;39:181-7.
7. Davson H, Segal MB. Physiology of the CSF and blood-brain barriers. Boca Raton (USA): CRC Press 1996.
8. Felgenhauer K, Schliep G, Rapic N. Evaluation of the blood-CSF barrier by protein gradients and the humoral immune response within the central nervous system. J Neurol Sci 1976;30:113-28.
9. Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta 1987;163:319-28.
10. Jacobi C, Reiber H, Felgenhauer K. The clinical relevance of locally produced carcinoembryonic antigen in cerebrospinal fluid. J Neurol 1986;233:358-61.
11. Clausen J. Proteins in cerebrospinal fluid not found in serum. Proc Soc Exp Biol Med 1961;107:170-2.
12. Felgenhauer K, Schadlich HJ, Nekic M. Beta trace-protein as marker for cerebrospinal fluid fistula. Klin Wochenschr 1987;65:764-8.
13. Blödorn B, Brück W, Tumani H, Michel U, Rieckmann P, Althans N, et al. Expression of the beta-trace protein in human pachymeninx as revealed by in situ hybridization and immunocytochemistry. J Neurosci Res 1999;57:730-4.
14. Tumani H, Nau R, Felgenhauer K. Beta-trace protein in cerebrospinal fluid: a blood-CSF barrier-related evaluation in neurological diseases. Ann Neurol 1998;44:882-9.
15. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-34.
16. Lewczuk P, Reiber H, Tumani H. Intercellular adhesion molecule-1 in cerebrospinal fluid - the evaluation of blood-derived and brain-derived fractions in neurological diseases. J Neuroimmunol 1998;87:156-61.
17. Martinez HA, Bell KP, Norenberg MD. Glutamine synthetase: glial localization in brain. Science 1977;195:1356-8.
18. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999;1450:191-231.
19. Lamers KJ, van-Engelen BG, Gabreels FJ, Hommes OR, Borm GF, Wevers RA. Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol Scand 1995;92:247-51.
20. Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol 1985;101:1371-8.
21. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-34.
22. Schaarschmidt H, Prange HW, Reiber H. Neuron-specific enolase concentrations in blood as a prognostic parameter in cerebrovascular diseases. Stroke 1994;25:558-65.
23. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278:179-90.
24. Tumani H, Nolker G, Reiber H. Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis. Neurology 1995;45:1663-70.
25. Brettschneider J, Claus A, Kassubek J, Tumani H. Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. J Neurol 2005; Epub April 1.
26. Reiber H. Flow rate of cerebrospinal fluid (CSF) - a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci 1994; 122:189-203.
27. Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997;41:326-33.
28. Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, et al. S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 1997;244:566-70.
29. Weber T, Tumani H, Holdorff B, Collinge J, Palmer M, Kretzschmar HA, et al. Transmission of Creutzfeldt-Jakob disease by handling of dura mater. Lancet 1993;341: 123-4.
30. Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225:210-2.
31. Steinhoff BJ, Tumani H, Otto M, Mursch K, Wiltfang J, Herrendorf G, et al. Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy. Epilepsy Res 1999;36:75-82.
32. Andreasen N, Vanmechelen E, van De Voorde A, Davidsson P, Hesse C, Tarvonen S, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow-up study. J Neurol Neurosurg Psychiatry 1998;64:298-305.
33. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Aβ42 and phosphorylated tau as biomarkers for Alzheimer's disease. Mol Neurobiol 2001;24:87-97.
34. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 2005;57:721-9.
35. Sussmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett 2003;353:57-60.
36. Brettschneider J, Maier M, Arda S, Claus A, Sussmuth SD, Kassubek J, et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler 2005;11:261-5.
37. Blennow K. CSF biomarkers for mild cognitive impairment. J Int Medicine 2004;256:224-34.
38. Acarin L, Gonzalez B, Castellano B, Castro AJ. Microglial response to N-methyl-D-aspartate-mediated excitotoxicity in the immature rat brain. J Comp Neurol 1996;367:361-74.
39. Agarwala S, Kalil RE. Axotomy-induced neuronal death and reactive astrogliosis in the lateral geniculate nucleus following a lesion of the visual cortex in the rat. J Comp Neurol 1998;392:252-63.
40. Tumani H, Reiber H, Steinhoff BJ, Felgenhauer K. Klinische Relevanz hirnspezifischer Proteine im Liquor und im Serum. Akt Neurologie 1999;26:S1(Abstract).
41. Tumani H, Smirnov A, Barchfeld S, Olgemöller U, Maier K, Lange P, et al. Inhibition of glutamine synthetase in rabbit pneumococcal meningitis is associated with neuronal apoptosis in the dentate gyrus. Glia 2000;30:11-8.
42. Norenberg MD. Astrocyte responses to CNS injury. J Neuropathol Exp Neurol 1994;53:213-20.
43. Tumani H, Shen G, Peter JB, Brück W. Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease? Arch Neurol 1999;56:1241-6.
44. Blennow K, Vanmechelen E. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. J Neural Transm Suppl 1998;53:223-35.
45. Tumani H, Tourtellotte WW, Peter JB, Felgenhauer K. Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. J Neurol Sci 1998;155:44-9.